Pascale Cony-Makhoul
Overview
Explore the profile of Pascale Cony-Makhoul including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Roy L, Chomel J, Guilhot J, Guerci-Bresler A, Escoffre-Barbe M, Giraudier S, et al.
Br J Haematol
. 2022 Oct;
200(2):175-186.
PMID: 36214090
Superior rates of deep molecular response (DMR) have been reported with the combination of tyrosine kinase inhibitors and pegylated-interferon-alpha (Peg-IFN) in patients with newly diagnosed chronic phase-chronic myeloid leukaemia (CP-CML)....
12.
Kubasch A, Giagounidis A, Metzgeroth G, Jonasova A, Herbst R, Torregrosa Diaz J, et al.
Leukemia
. 2022 Sep;
36(10):2519-2527.
PMID: 36071100
The EUROPE phase 2 trial investigated the predictive value of biomarkers on the clinical efficacy of single agent romiplostim (ROM) treatment in patients with lower-risk myelodysplastic neoplasms (LR-MDS) and thrombocytopenia...
13.
Johnson-Ansah H, Maneglier B, Huguet F, Legros L, Escoffre-Barbe M, Gardembas M, et al.
Pharmaceutics
. 2022 Aug;
14(8).
PMID: 36015302
The registered dose for imatinib is 400 mg/d, despite high inter-patient variability in imatinib plasmatic exposure. Therapeutic drug monitoring (TDM) is routinely used to maximize a drug’s efficacy or tolerance....
14.
Dulucq S, Hayette S, Cayuela J, Bauduer F, Chabane K, Chevallier P, et al.
Haematologica
. 2022 Aug;
107(12):2944-2949.
PMID: 35924576
No abstract available.
15.
Sobas M, Kiladjian J, Beauverd Y, Curto-Garcia N, Sadjadian P, Shih L, et al.
Blood Adv
. 2022 Jul;
6(17):5171-5183.
PMID: 35802458
Myeloproliferative neoplasms (MPNs) are uncommon in children/young adults. Here, we present data on unselected patients diagnosed before 25 years of age included from 38 centers in 15 countries. Sequential patients...
16.
Dulucq S, Nicolini F, Rea D, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, et al.
Haematologica
. 2022 May;
107(12):2859-2869.
PMID: 35615931
Discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia is feasible in clinical practice based on recently published international recommendations. Nevertheless, factors predictive of molecular recurrence have not...
17.
Jouzier C, Cherait A, Cony-Makhoul P, Hamel J, Veloso M, Thepot S, et al.
Transfusion
. 2022 Apr;
62(5):961-973.
PMID: 35452143
Background: MDS-RS patients are characterized by chronic anemia and a low risk of Acute Myeloid Leukemia (AML) progression and they generally become Red Blood Cell (RBC) transfusion dependent (TD). Study...
18.
Canet J, Cony-Makhoul P, Orazio S, Cornet E, Troussard X, Maynadie M, et al.
Cancer Med
. 2021 Sep;
10(20):6959-6970.
PMID: 34551198
Introduction: Since 2009, multiple randomized trials have shown faster and deeper responses in CML patients treated with new-generation TKI (NG-TKI) compared to those treated with imatinib (IM). Are the same...
19.
Rousselot P, Mollica L, Guilhot J, Guerci A, Nicolini F, Etienne G, et al.
Br J Haematol
. 2021 Jul;
194(2):393-402.
PMID: 34195988
Dasatinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor approved for patients with chronic myeloid leukaemia (CML). Dasatinib 100 mg per day is associated with an increased risk of pleural effusion...
20.
Pegliasco J, Hirsch P, Marzac C, Isnard F, Meniane J, Deswarte C, et al.
Leukemia
. 2021 Jun;
36(1):126-137.
PMID: 34172895
The germline predisposition associated with the autosomal dominant inheritance of the 14q32 duplication implicating ATG2B/GSKIP genes is characterized by a wide clinical spectrum of myeloid neoplasms. We analyzed 12 asymptomatic...